Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Cited by (516)

Items 401–500 of 516

1. A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization
   John Misasi, Ronnie R. Wei, Lingshu Wang, Amarendra Pegu, Chih‐Jen Wei, Olamide K. Oloniniyi, Tongqing Zhou, Juan I. Moliva, Bingchun Zhao, Misook Choe et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
2. Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article
   Nawal Abd El‐Baky, Amro Abd Al Fattah Amara · 2022 · Frontiers in Medicine
3. Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2
   Olivia Cabanillas-Bernal, Blanca J. Valdovinos-Navarro, Karla Cervantes-Luévano, Noemí Sánchez-Campos, Alexei F. Licea-Navarro · 2023 · Frontiers in Immunology
4. Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps
   Soumya G. Remesh, Gregory E. Merz, Axel F. Brilot, Un Seng Chio, Alexandrea N. Rizo, Thomas H. Pospiech, Irene Lui, Mathew T. Laurie, Jeff E. Glasgow, Chau Q. Le et al. · 2023 · Structure
5. A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo
   John Misasi, Ronnie R. Wei, Lingshu Wang, Amarendra Pegu, Chih‐Jen Wei, Olamide K. Oloniniyi, Tongqing Zhou, Juan I. Moliva, Bingchun Zhao, Misook Choe et al. · 2024 · Science Translational Medicine
6. Nanoparticle-Supported, Rapid, Digital Quantification of Neutralizing Antibodies Against SARS-CoV-2 Variants
   Seyedsina Mirjalili, Md Ashif Ikbal, Ching‐Wen Hou, Maziyar Kalateh Mohammadi, Yeji Choi, Laimonas Kelbauskas, Laura A. VanBlargan, Brenda G. Hogue, Vel Murugan, Michael Diamond et al. · 2024 · Biosensors and Bioelectronics
7. Molecular Farming: Sustainable Manufacturing of Vaccines, Antibodies, and Other Therapeutic Substances
   Kaisar Ahmad Bhat, Lubna Tariq, Aadil Ayaz, Madhiya Manzoor, Sajad Majeed Zargar, Ali Asghar Shah · 2022 · Springer eBooks
8. A covalent opsonization approach to enhance synthetic immunity against viral escape variants
   Eden Kapcan, Anthony F. Rullo · 2023 · Cell Reports Physical Science
9. Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex
   Minoru Tada, Michihiko Aoyama, Akiko Ishii‐Watabe · 2023 · mAbs
10. SARS-CoV-2 and Epstein–Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests
    Johannes Roessler, Dagmar Pich, Verena Krähling, Stephan Becker, Oliver Till Keppler, Reinhard Zeidler, Wolfgang Hammerschmidt · 2023 · Biomedicines
11. Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants
    Kan Li, Richard H. C. Huntwork, G. Horn, Milite Abraha, K. Hastie, Hao-Yang Li, Vamseedhar Rayaprolu, Eduardo Olmedillas, E. Feeney, Ken Cronin et al. · 2023 · Journal of Virology
12. To be remembered: B cell memory response against SARS‐CoV ‐2 and its variants in vaccinated and unvaccinated individuals
    Nafees Ahmed, Atharv Athavale, Ankita Harishchandra Tripathi, Adarsh Subramaniam, Santosh Kumar Upadhyay, Anil Kumar Pandey, Ramesh Chandra Rai, Amit Awasthi · 2023 · Scandinavian Journal of Immunology
13. Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies
    Jun-biao Xue, Sheng-Ce Tao · 2021 · Current Medical Science
14. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
    Rong Xiang, Yang Wang, Lili Wang, Xiaoqian Deng, Shanshan Huo, Shibo Jiang, Fei Yu · 2021 · Current Opinion in Virology
15. Impact of New Variants on SAR-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions
    Mary Hongying Cheng, James Krieger, Yufei Xiang, Burak Kaynak, Yi Shi, Moshe Arditi, İvet Bahar · 2021 · SSRN Electronic Journal
16. Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
    Marco Aurelio Díaz-Salinas, Qi Li, Monir Ejemel, Leonid Yurkovetskiy, Jeremy Luban, Kuang Shen, Yang Wang, James B. Munro · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
17. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
    Wenjuan Du, Daniel L. Hurdiss, Dubravka Drabek, Anna Z. Mykytyn, Franziska Karola Kaiser, M. C. González-Hernández, Diego Muñoz‐Santos, Mart Matthias Lamers, Rien van Haperen, Wentao Li et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
18. Mutational Scanning and Binding Free Energy Computations of the SARS-CoV-2 Spike Complexes with Distinct Groups of Neutralizing Antibodies: Energetic Drivers of Convergent Evolution of Binding Affinity and Immune Escape Hotspots
    Mohammed Alshahrani, Vedant Parikh, Brandon Foley, Nishank Raisinghani, Gennady M. Verkhivker · 2025 · International Journal of Molecular Sciences
19. A linear B-cell epitope close to the furin cleavage site within the S1 domain of SARS-CoV-2 Spike protein discriminates the humoral immune response of nucleic acid- and protein-based vaccine cohorts
    Peter Lorenz, Felix Steinbeck, Franz Mai, Emil Christian Reisinger, Brigitte Müller‐Hilke · 2023 · Frontiers in Immunology
20. In silico antibody engineering for SARS-CoV-2 detection
    Didac Martí, Eduard Martín-Martínez, Juan Torras, Oscar Bertrán, Pau Turón, Carlos Alemán · 2021 · Computational and Structural Biotechnology Journal
21. Determining the International Spread of B.1.1.523 SARS-CoV-2 Lineage with a Set of Mutations Highly Associated with Reduced Immune Neutralization
    Lukas Žemaitis, Gediminas Alzbutas, Dovydas Gečys, Andrey B. Komissarov, Arnoldas Pautienius, Rasa Ugenskienė, Marius Šukys, Vaiva Lesauskaitė · 2022 · Microorganisms
22. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization
    Maria G. Byazrova, Pia Gattinger, Ekaterina A. Astakhova, Gerhard Höfer, Musa Rakhimovich Khaitov, Alexander V. Filatov, Rudolf Valenta · 2023 · International Journal of Molecular Sciences
23. A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
    Chunyin Gu, Xiaodan Cao, Zongda Wang, Xue Hu, Yanfeng Yao, Yiwu Zhou, Peipei Liu, Xiaowu Liu, Ge Gao, Xiao Hu et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
24. Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron
    A. Choudhary, M. Lerman, David Calianese, Salman Khan, J. Hunt, A. Nikaein, W. Honnen, D. Jaijyan, E. Kalu, Abraham Pinter · 2022 · medRxiv
25. Hybrid immunity elicits potent cross-variant ADCC against SARS-CoV-2 through a combination of anti-S1 and S2 antibodies
    Michael D. Grant, Kirsten Bentley, Ceri Alan Fielding, Keeley M. Hatfield, Danielle P. Ings, Debbie O. A. Harnum, Eddie C. Y. Wang, Richard James Stanton, Kayla A. Holder · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
26. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines
    Jimin Lee, Cameron Stewart, Alexandra Schaefer, Elizabeth M. Leaf, Young‐Jun Park, Daniel E. Asarnow, John M. Powers, Catherine Treichel, Davide Corti, Ralph Steven Baric et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
27. SARS-CoV-2 vaccines elicit differential Fc effector functions
    Nelia P. Manamela, Boitumelo M. Motsoeneng, Holly Spencer, Tandile Hermanus, Nonkululeko B. Mzindle, Frances Ayres, Zanele Makhado, Rudolph Serage, Glenda Gray, Linda‐Gail Bekker et al. · 2025 · iScience
28. Allosteric Control Overcomes Steric Limitations for Neutralizing Antibodies Targeting Conserved Binding Epitopes of the SARS-CoV-2 Spike Protein: Exploring the Intersection of Binding, Allostery, and Immune Escape with a Multimodal Computational Approach
    Mohammed Alshahrani, Vedant Parikh, Brandon Foley, Gennady M. Verkhivker · 2025 · Biomolecules
29. IgG‐Bridging–Seeded Synergistic Aggregation of SARS‐CoV‐2 Spikes Underlies Potent Neutralization by a Low‐Affinity Antibody
    Nian-Nian Lv, Peng Chen, X. Dai, Hu Xu, Zi-Heng Li, Zelin Shan, Jin-Qian Li, Feng-Lin Guo, Yuan-Fang Chen, Jia-Yi Li et al. · 2025 · bioRxiv
30. Neutralization of SARS-CoV-2 by IgM-14 via engagement of two distinct spike epitopes
    Yan Wang, Yanping Hu, Zhiqiang Ku, Jason Yeung, Jing Zou, Michael Woodson, Nikolai S. Prokhorov, Ekaterina S. Knyazhanskaya, Haiqing Zhao, Michael B. Sherman et al. · 2026 · PLoS Pathogens
31. Bispecific Antibodies as an Alternative to Antibody Cocktails for SARS-CoV-2: A Mini- Review
    Gavin Yuen, Saundarai Bhanot, Jeremy P. Steen, Minahil Syed, Austin Albert Mardon · 2020 · Journal of Immunological Sciences
32. Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1
    Tatsuhiko Ozawa, Yoshiki Ikeda, Liuan Chen, Rigel Suzuki, Atsushi Hoshino, Akira Noguchi, Shunsuke Kita, Yuki Anraku, Emiko Igarashi, Yumiko Saga et al. · 2024 · Structure
33. A benchmark for evaluation of structure-based online tools for antibody-antigen binding affinity
    Xu Jiayi, Jianting Gong, Xiaochen Bo, Yigang Tong, Zilin Ren, Ming Ni · 2024 · Biophysical Chemistry
34. Low Antibody-Dependent Enhancement of Viral Entry Activity Supports the Safety of Inactivated SARS-CoV-2 Vaccines
    Xiaofang Peng, Yuru Han, Song Xue, Yunjiao Zhou, Weiyu Jiang, Anqi Xia, Wei Wu, Yidan Gao, Fan Wu, Qiao Wang · 2025 · Vaccines
35. Murine antibody 4B1D3 exhibits broad cross-reactivity and neutralizing activity against SARS-CoV-2 variants
    Mariângela de Oliveira Silva, Isabela Pazotti Daher, Catarina Harumi Oda Ibrahim, Edmárcia Elisa de Souza, Edilberto Postól, Raquel Elaine de Alencar, Guilherme Antônio de Souza Silva, Rodolfo Ferreira Marques, Flávia Lopes Adami, Viviane Schuch et al. · 2025 · Virology
36. Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein
    Lokpati Mishra, Tusar Bandyopadhyay · 2022 · Journal of Biomolecular Structure and Dynamics
37. SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus
    J. Muñoz-Basagoiti, D. Perez-Zsolt, J. Carrillo, J. Blanco, B. Clotet, N. Izquierdo-Useros · 2021 · Membranes
38. Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods
    Marion F. S. Fischer, James E. Crowe, Jens Meiler · 2022 · PLoS Computational Biology
39. Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases
    Thomas Sécher, Nathalie Heuzé‐Vourc'h · 2023 · AAPS introductions in the pharmaceutical sciences
40. Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
    Sai Luo, Jun Zhang, Alex J.B. Kreutzberger, Amanda Eaton, Robert J. Edwards, Changbin Jing, Hai‐Qiang Dai, Gregory D. Sempowski, Kenneth D. Cronin, Robert Parks et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
41. Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China
    Yongmei Liu, Guo Yaping, Haoting Zhan, Xin Liu, Xiaomeng Li, Jingjing Cui, Haolong Li, Sha Feng, Linlin Cheng, Xiaoyan Li et al. · 2024 · BMC Infectious Diseases
42. Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters
    Núria Pedreño-López, Ferran Tarrés-Freixas, Carla Usai, Dàlia Raïch Regué, Susana Benet, Erola Ainsua‐Enrich, Julieta Carabelli, Edwards Pradenas, Carlos Ávila‐Nieto, Núria Roca et al. · 2025 · Communications Biology
43. Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development
    Taruna Ikrar, Wachyudi Muchsin, Alfi Sophian · 2026 · Journal of Virological Methods
44. Impact of antibody-level on viral shedding in B.1.617.2 (Delta) variant-infected patients analyzed using a joint model of longitudinal and time-to-event data
    Yi Bing Yin, Ting Zeng, Miao Lai, Zemin Luan, Kai Wang, Yuhang Ma, Zhiliang Hu, Kai Wang, Zhihang Peng · 2023 · Mathematical Biosciences & Engineering
45. Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection
    Kayla A. Holder, Danielle P. Ings, Kathleen E. Fifield, David A Barnes, Keeley A. Barnable, Debbie O. A. Harnum, Rodney S. Russell, Michael D. Grant · 2024 · The Journal of Immunology
46. Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants
    Indrani Das Jana, Kawkab Kanjo, Subhanita Roy, Munmun Bhasin, Shatarupa Bhattacharya, Indranath Banerjee, Subhasis Jana, Arjun Chatterjee, Alok Chakraborty, Suman Kumar Chakraborty et al. · 2025 · Journal of Virology
47. Does Covera-19 know ‘when to hold ‘em or ‘when to fold ‘em? A translational thought experiment
    Gerald Dieter Griffin · 2021 · Translational Medicine Communications
48. COVID-19: sudden and dramatic upsurge in the number of cases in India
    Ketul S. Barot, Saloni H. Naik, M. Patel, S. Mankad, Akash A. Patel, Pankti S. Pandya, Vishwa V. Patel, S. Nimbalkar · 2021 · International Journal of Community Medicine and Public Health
49. A SARS-CoV-2-ellenes antitestekkel végzett terápia helye a COVID–19 kezelésében
    Ákos Fábián · 2021 · Orvosi Hetilap
50. Analysis of Sars-CoV-2 RBD Mutations in Khuzestan Province, Iran - A Retrospective Study, 2021
    Masoud Beheshti, Niloofar Neisi, Mehdi Parsanahad, Mojtaba Rasti, Roya Pirmoradi · 2023 · Iranian Journal of Medical Microbiology
51. Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccine
    Yangtao Wu, Xiaofen Huang, Lunzhi Yuan, Shaojuan Wang, Yali Zhang, Hualong Xiong, Rirong Chen, Jian Ma, Ruoyao Qi, Meifeng Nie et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
52. MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans
    Andrea Castro, Kivilcim Ozturk, M. Zanetti, H. Carter · 2020 · bioRxiv
53. Mapping Potential Antigenic Drift Sites (PADS) on SARS-CoV-2 Spike in Continuous Epitope-Paratope Space
    Nathaniel L. Miller, Thomas Clark, Rahul Raman, Ram Sasisekharan · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
54. Dissecting Molecular Determinants of Mutational Escape Mechanisms in the SARS-CoV-2 Spike Protein Complexes with Nanobodies: Atomistic Simulations and Ensemble-Based Deep Mutational Scanning of Protein Stability and Binding Interactions
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Preprints.org
55. Predicting spike protein NTD mutations of SARS-CoV-2 causing immune escape by molecular dynamics simulations
    Liping Zhou, Leyun Wu, Cheng Peng, Yanqing Yang, Yulong Shi, Zhijian Xu, Weiliang Zhu · 2021
56. A mRNA vaccine encoding for a RBD 60-mer nanoparticle elicits neutralizing antibodies and protective immunity against the SARS-CoV-2 delta variant in transgenic K18-hACE2 mice
    Pascal Brandys, Xavier Montagutelli, Irena Merenkova, G. Tuba Barut, Volker Thiel, Nicholas J. Schork, Bettina Salome Trüeb, Laurine Conquet, Aihua Deng, Aleksandar Antanasijevic et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
57. Structural and Computational Design of a SARS-2 Spike Antigen with Increased Receptor Binding Domain Exposure and Improved Immunogenicity
    James A. Williams, Marco Biancucci, Laura N. Lessen, Sai Tian, Ankita Balsaraf, Lynn Chen, Chelsy C. Chesterman, Giulietta Maruggi, Sarah Vandepaer, Ying Huang et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
58. Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
    J. Seow, Z. A. Shalim, C. Graham, Simon Kimuda, Aswin Pillai, T. Lechmere, Ashwini Kurshan, Atika M. Khimji, L. Snell, G. Nebbia et al. · 2023 · bioRxiv
59. Protective non-neutralizing mAbs Ab94 and Ab81 retain high-affinity and potent Fc-mediated function against SARS-CoV-2 variants from Omicron to XBB1.5
    Arman Izadi, Magdalena Godzwon, Mats Ohlin, Pontus Nordenfelt · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
60. Engineering customized viral receptors for various coronaviruses
    Peng Liu, Meiling Huang, Hua Guo, Junyu Si, Yuanmei Chen, Chunli Wang, Yu Xiao, Lulu Shi, Qing Xiong, Chenbao Ma et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
61. High-Throughput Antibody Neutralization Screening in Massively Parallel Droplet Arrays
    Matías Gutiérrez-González, Ahmed S. Fahad, Cyrille L. Delley, Cheng-Yu Chung, Shuyan Jin, Nicoleen Boyle, Matheus Oliveira de Souza, Azady Pirhanov, Nicolás M. S. Gálvez, Camila Tenorio França et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
62. Unconventional linkers facilitate potent stabilized coronavirus stem antibody responses following nanoparticle vaccination
    Christian K. O. Dzuvor, Sydney P. Moak, Lindsay R. McManus, Abigail E. Dzordzorme, Lamount R. Evanson, Tae‐Woo Kim, Abigail Thomas, Olayimika Adeyemi, Valerie Foley, Aditi Limaye et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
63. In silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies
    Yang, Yanqing, Qiao, Lulu, Jiang, Yangwei, Wang, Zhiye, Zhang, Dong, Buratto, Damiano, Huang, Liquan, Zhou, Ruhong · 2026 · eLife
64. In silico design and validation of high-affinity RNA aptamers for SARS-CoV-2 comparable to neutralizing antibodies
    Yang, Yanqing, Qiao, Lulu, Jiang, Yangwei, Wang, Zhiye, Zhang, Dong, Buratto, Damiano, Huang, Liquan, Zhou, Ruhong · 2026 · eLife
65. Impact of the SARS-CoV-2 S-protein G476S mutation on the interaction with human ACE-2 receptor and neutralizing antibodies
    A. Kwarteng, Ebenezer Asiedu, A. Sylverken, A. Larbi, P. Twumasi · 2021 · Research Square
66. Evaluation of efficacy of the amino acid-peptide complex administered intragastrically to golden hamsters experimentally infected with SARS-CoV-2
    Denis Sergeevich Laptev, G. A. Protasova, Sergey Gervasievich Petunov, AS Radilov, SV Chepur, AS Gogolevskiy, VA Myasnikov, MA Tyunin, AV Smirnova · 2021 · Medicine of Extreme Situations
67. Unbinding of hACE2 and Inhibitors from the Receptor Binding Domain of SARS-CoV-2 Spike Protein
    Lokpati Mishra, Tusar Bandyopadhyay · 2021
68. COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentration
    David Edward Williams · 2021 · Research Square
69. Protective characteristics of COVID-19 convalescent and post-vaccination IgG antibodies
    Melvin E. Klegerman, Tao Peng, Ira Seferovich, Mohammad H. Rahbar, Manouchehr Hessabi, Amirali Tahanan, Audrey R. Wanger, Carolyn Z. Grimes, Luis Ostrosky‐Zeichner, Kent J. Koster et al. · 2021 · medRxiv
70. Why is 'City of Death' the Best Doctor Who Story?
    Alan McKee · 2007 · Manchester University Press eBooks
71. COVID 19 breakthrough infection risk: a simple physical model describing the dependence on antibody concentration
    David Edward Williams · 2021 · Research Square
72. The Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614 Mutant: Conformational Plasticity and Frustration-Driven Allostery as Energetic Drivers of Highly Transmissible Spike Variant
    Gennady M. Verkhivker, Steve Agajanian, Ryan Kassab, Keerthi Krishnan · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
73. Sialic acid and fucose residues on the SARS-CoV-2 receptor binding domain modulate IgG reactivity
    Ebba Samuelsson, Ekaterina E. Mirgorodskaya, Kristina Nyström, Malin Bäckström, Jan‐Åke Liljeqvist, Rickard Nordén · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
74. Predicting the Potential Effect of E484K Mutation on the Binding of 28 Antibodies to the Spike Protein of SARS-CoV-2 by Molecular Dynamics Simulation and Free Energy Calculation
    Leyun Wu, Cheng Peng, Zhijian Xu, Weiliang Zhu · 2021 · ChemRxiv
75. Faculty Opinions recommendation of Designed proteins assemble antibodies into modular nanocages.
    Takashi Hashimoto · 2021 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
76. On Correlation between Structural Properties and Viral Escape Measurements from Deep Mutational Scanning
    Leili Zhang, Giacomo Domeniconi, Chih-Chieh Yang · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
77. Profilaxia specifică a infecției cu SARS-COV-2, între clasic și modern | [Specific prophylaxis of SARS-COV-2 infection, between classical and modern]
    Elena Mihaela Constantinescu, Cristian-Adrian Constantinescu · 2022 · Jurnal Medical Brasovean
78. Hierarchical Computational Modeling and Dynamic Network Analysis of Allosteric Regulation in the SARS-CoV-2 Spike Omicron Trimer Structures: Omicron Mutations Cooperate to Allosterically Control Balance of Protein Stability and Conformational Adaptability
    Gennady M. Verkhivker, Steve Agajanian, Ryan Kassab, Keerthi Krishnan · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
79. Impact of the SARS-CoV-2 S-protein G476S mutation on the interaction with human ACE-2 receptor and neutralizing antibodies
    Alexander Kwarteng, Ebenezer Asiedu, Augustina Angelina Sylverken, Amma Aboagyewa Larbi, Peter Twumasi · 2021 · Research Square
80. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2
    Prerna Arora, Amy Madeleine Kempf, Inga Nehlmeier, Luise Graichen, Sebastian R. Schulz, Anne Cossmann, Alexandra Dopfer‐Jablonka, Martin Sebastian Winkler, Hans‐Martin Jäck, Georg M. N. Behrens et al. · 2022 · Cellular and Molecular Immunology
81. A core epitope targeting antibody of SARS-CoV-2
    Simeng Zhao, Fengjiang Liu, Shizhen Qiu, Qiaoshuai Lan, Yiran Wu, Wei Xu, Junzi Ke, Jie E Yang, Xiaoyan Liu, Kun Wang et al. · 2022 · Protein & Cell
82. An alpaca-derived nanobody recognizes a unique conserved epitope and retains potent activity against the SARS-CoV-2 omicron variant
    N. Modhiran, S. Lauer, A. Amarilla, P. Hewins, Sara Lopes van den Broek, Y. Low, Nazia Thakur, Benjamin Liang, Guillermo Valenzuela Nieto, James Jung et al. · 2022 · bioRxiv
83. A Novel Monoclonal Antibody Targeting a Large Surface of the Receptor Binding Motif Shows Pan-neutralizing SARS-CoV-2 Activity Including BQ.1.1 Variant
    Leire de Campos‐Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas, Natalia Rodrigo Melero, Diego Carlero, Sílvia Marfil, Anna Pons-Grífols, M. Teresa Bueno-Carrasco et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
84. Redesign computacional de anticorpos específicos para o domínio de ligação ao receptor (RBD) da proteína spike de SARS-CoV-2 com afinidade de ligação aumentada às sublinhagens ômicron
    Cecilia Pereira · 2023
85. Cryo-EM reveals variation in structural motifs within animal SARS-related coronavirus spike proteins
    Mihnea Bostina, Francesca R. Hills, Alice-Roza Eruera, Fátima Jorge, Richard A. Easingwood, James Hodgkinson‐Bean, Simon H. J. Brown, James C. Bouwer, Laura N. Burga · 2023 · Research Square
86. Chronic Shedding of a SARS-CoV-2 Alpha Variant Lineage Q.3/Q.4 in Wastewater
    Michael J. Conway, Hannah Yang, Lauren A. Revord, Avery S. Ward, Jackson D. Abel, Maggie R. Williams, Rebecca Lynne Uzarski, Elizabeth Wheeler Alm · 2023 · medRxiv
87. Engineered Therapeutic Antibody Against SARS-CoV-2
    Monrat Chulanetra · 2023 · Current Clinical Microbiology Reports
88. COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2
    Charles W. Stratton, Yi‐Wei Tang · 2024 · Elsevier eBooks
89. Current Progress in Genomic and Genetic Research on Human Viral Diseases
    2024 · Frontiers research topics
90. Research progress in Fc‐effector functions against SARS‐CoV‐2
    Rongyuan Gao, Chenchen Feng, Zizhang Sheng, Feng Li, Dan Wang · 2024 · Journal of Medical Virology
91. SARS-CoV-2 Spike Opening Dynamics and Energetics Reveal the Individual Roles of Glycans and Their Collective Impact
    Yui Tik Pang · 2024 · Springer theses
92. Expression and Purification of SARS‐related Spike Glycoproteins for Cryo‐EM Analysis
    Francesca R. Hills, Fátima Jorge, Laura N. Burga, Mihnea Bostina · 2025 · Current Protocols
93. Exploring Diverse Binding Mechanisms of Broadly Neutralizing Antibodies S309, S304, CYFN-1006 and VIR-7229 Targeting SARS-CoV-2 Spike Omicron Variants: Integrative Computational Modeling Reveals Balance of Evolutionary and Dynamic Adaptability in Shaping Molecular Determinants of Immune Escape
    Mohammed Alshahrani, Vedant Parikh, Brandon Foley, Gennady M. Verkhivker · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
94. Exploring Dynamic Modulation of Binding, Allostery and Immune Resistance in the SARS-CoV-2 Spike Complexes with Classes of Antibodies Targeting Cryptic Binding Sites: Antibody-Specific Augmentations of Conserved Allosteric Architecture Can Influence Evolution of Viral Escape
    Mohammed Alshahrani, Vedant Parikh, Brandon Foley, Gennady M. Verkhivker · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
95. Deciphering the Mechanistic Continuum of Broadly Neutralizing Class 4 Antibodies Targeting Conserved Cryptic Epitopes of the SARS-CoV-2 Spike Protein : Operating at the Intersection of Binding, Allostery and Immune Escape
    Mohammed Alshahrani, Vedant Parikh, Brandon Foley, Gennady M. Verkhivker · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
96. Elucidating the Humoral Immune Response to SARS-CoV-2: Isolation and Characterization of Monoclonal Antibodies from Convalescent COVID-19 Patients
    Yiran Shen, Jason J. Thornton, Alexandria Voigt, Apichai Tuanyok, Cuong Quoc Nguyen · 2025 · medRxiv
97. Computational Analysis of Mutation Effect on SARS-CoV-2 Spike Protein Structures
    Shivani Thakur, Rukmankesh Mehra · 2025 · Progress in theoretical chemistry and physics
98. Structural Characterization and AI‐Enhanced Modeling of a Broadly Neutralizing Camelid Antibody Against SARS‐CoV‐2 Variants
    Katja Hanack, Urszula Orzeł, Anja Schlör, Sourabh Mehta, Anandi Krishnan, Sławomir Filipek, Rushika Patel, Madhvi N. Joshi, Markus Hoffmann, Stefan Pöhlmann et al. · 2025 · Advanced Therapeutics
99. Additional file 1 of Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features
    Hao D. Cheng, Karen G. Dowell, Bailey-Kellogg, Chris, Brittany A. Goods, John Christopher Love, Guido Ferrari, Galit Alter, Johannes S. Gach, Donald N. Forthal, George K. Lewis et al. · 2021 · Figshare
100. Additional file 1 of Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
     Norma A. Valdez‐Cruz, García-Hernández, Enrique, Clara Espitia, Laura Cobos-Marín, Claudia Altamirano, Carlos G. Bando-Campos, Luis Fernando Cofas‐Vargas, Enrique Wenceslao Coronado-Aceves, Ricardo A. González-Hernández, Pablo Hernández‐Peralta et al. · 2021 · Figshare